Modopar (Benserazide Hydrochloride, Levodopa)

Levodopa/Benserazide, the active ingredient in Modopar, is an antiparkinson agent presented as oral tablets for oral use. It is indicated for the treatment of Parkinson's disease by addressing dopamine deficiency in the central nervous system. GNH USA supplies Modopar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modopar is an antiparkinson medication that targets the dopaminergic pathway in Parkinson's disease. - Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor. - Early‑stage Parkinson's disease: enhances overall motor function and daily activity performance. - Advanced Parkinson's disease with motor fluctuations: provides more stable dopamine levels to reduce “off” periods.

Modopar may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea - Vomiting - Dizziness or light‑headedness - Orthostatic hypotension - Headache - Insomnia

Serious or Rare Side Effects: - Dyskinesia (involuntary movements) - Hallucinations or other psychiatric disturbances - Severe hypotension or arrhythmias - Neuroleptic malignant syndrome (very rare) - Severe allergic reactions such as skin rash or angioedema

When prescribing Modopar, clinicians should consider several safety measures. - Blood pressure monitoring: watch for orthostatic hypotension, especially at treatment initiation. - Renal function assessment: dose may need adjustment in patients with impaired renal clearance. - Psychiatric history review: patients with psychosis may be more susceptible to hallucinations. - Elderly patients: start at low doses and titrate slowly to reduce adverse events. - Discontinuation: avoid abrupt cessation to prevent withdrawal symptoms; taper gradually. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Modopar can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: may cause hypertensive crisis when combined with levodopa. - MAO‑B inhibitors plus other dopaminergic agents: increase risk of severe hypotension and dyskinesia. - Antipsychotics (e.g., haloperidol): can antagonize levodopa’s effect and worsen Parkinsonian symptoms.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: additive blood‑pressure‑lowering effect may require dose adjustment. - Iron or calcium supplements: reduce levodopa absorption; separate administration by at least 2 hours. - High‑protein meals: may compete for transport across the gut wall, decreasing levodopa bioavailability.